PPI-1011 post-treatment neuroprotection of striatal dopamine and its metabolites.
- Edith Miville-Godbout (2558308)
- Mélanie Bourque (2558302)
- Marc Morissette (2558296)
- Sara Al-Sweidi (2558317)
- Tara Smith (2558311)
- Asuka Mochizuki (2558320)
- Vijitha Senanayake (2558305)
- Dushmanthi Jayasinghe (2558293)
- Li Wang (15202)
- Dayan Goodenowe (2558314)
- Thérèse Di Paolo (2558299)
Publication date
March 2016
DOIAbstract
<p>Effect of MPTP and PPI-1011 treatment on striatal A) DA contents (<i>F</i><sub>4,49</sub> = 15.76, <i>p</i> < 0.0001) and its metabolites B) DOPAC (<i>F</i><sub>4,49</sub> = 10.53, <i>p</i> < 0.0001), C) 3-MT (<i>F</i><sub>4,49</sub> = 5.59, <i>p</i> = 0.0009) and D) HVA (<i>F</i><sub>4,49</sub> = 6.20, <i>p</i> = 0.0004), as well as E) DOPAC/DA (<i>F</i><sub>4,49</sub> = 4.87, <i>p</i> = 0.002), F) 3-MT/DA (<i>F</i><sub>4,49</sub> = 3.92, <i>p</i> = 0.008) and G) HVA/DA (<i>F</i><sub>4,49</sub> = 8.60, <i>p</i> < 0.0001) ratios. Values shown are the means (ng/mg of proteins) ± S.E.M. of 9–14 mice per group. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 vs control; † p < 0.05 vs MPTP.</p
Add to ORKG